News of Note—Roche's blockbuster licensing deal; FibroGen's roxadustat application and more

23rd December 2019 Uncategorised 0

As we highlight some of our top special reports this year, here’s news we didn’t want readers to miss. In the day’s biggest development, Roche picked up ex-U.S. rights to Sarepta’s Duchenne muscular dystrophy gene therapy for more than $1 billion up front. AstraZeneca, FibroGen, Johnson & Johnson also made headlines of their own.

More: News of Note—Roche's blockbuster licensing deal; FibroGen's roxadustat application and more
Source: fierce